Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) – HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Dogwood Therapeutics in a report issued on Tuesday, May 19th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.32). HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at $0.14 EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.60) EPS.
Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07.
Read Our Latest Stock Report on Dogwood Therapeutics
Dogwood Therapeutics Price Performance
Shares of DWTX stock opened at $1.84 on Thursday. The stock has a market capitalization of $61.88 million, a PE ratio of -0.17 and a beta of 1.68. The business’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $3.52. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.05% of the company’s stock.
About Dogwood Therapeutics
Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.
Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.
Recommended Stories
- Five stocks we like better than Dogwood Therapeutics
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
